vedolizumab   Click here for help

GtoPdb Ligand ID: 7437

Synonyms: Entyvio® | LDP-02 | LDP02 | MLN-0002 | MLN-002 | MLN002
Approved drug Immunopharmacology Ligand
vedolizumab is an approved drug (FDA and EMA (2014))
Compound class: Antibody
Comment: Vedolizumab is a gut-selective monoclonal antibody that acts as an integrin antagonist by binding to α4β7 integrins on the surface of gastrointestinal-homing T lymphocytes.

Biosimilars:
NameTrade nameCompanyClinical PhaseIndications
PB016 n/aPolpharma Biologics/Fresenius KabiPhase 3moderate-severe active ulcerative colitis and Crohn's disease
Click here for help
Classification Click here for help
Compound class Antibody
Approved drug? Yes. EU EMA (2014)  |  US FDA (2014)
International Nonproprietary Names Click here for help
INN number INN
9093 vedolizumab
Synonyms Click here for help
Entyvio® | LDP-02 | LDP02 | MLN-0002 | MLN-002 | MLN002
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 300
Other databases
GtoPdb PubChem SID 178104009
PubChem SID 178104009
Search PubMed clinical trials vedolizumab
Search PubMed titles vedolizumab
Search PubMed titles/abstracts vedolizumab
Wikipedia Vedolizumab